• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Inspire Medical Systems, Inc. Announces Preliminary Results for the Fourth Quarter and Full Year 2024 and Provides Initial 2025 Revenue Guidance

    1/13/25 6:45:00 AM ET
    $INSP
    Medical/Dental Instruments
    Health Care
    Get the next $INSP alert in real time by email

    MINNEAPOLIS, Minn, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) ("Inspire", or the "Company"), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today announced certain preliminary, unaudited results for the fourth quarter and full year ended December 31, 2024, and provided its initial full year 2025 revenue guidance.

    Preliminary, Unaudited Fourth Quarter and Full Year 2024 Revenue and Recent Business Highlights

    • Revenue for the fourth quarter of 2024 is anticipated to be in the range of $239.5 million to $239.7 million, an approximately 25% increase over the same quarter of 2023
    • Revenue for full year 2024 is anticipated to be in the range of $802.6 million to $802.8 million, an approximately 28% increase over full year 2023
    • Activated 72 new centers in the U.S. in the fourth quarter of 2024, bringing the total to 1,435 U.S. medical centers implanting Inspire therapy
    • Created 12 new sales territories in the U.S. in the fourth quarter of 2024, bringing the total to 335 U.S. sales territories
    • Initiated the soft launch of the Inspire V neurostimulator with over 40 implants completed in Singapore and the U.S.
    • Implemented a new organizational structure intended to drive continued growth

    Initial Full Year 2025 Revenue Guidance

    • Revenue for full year 2025 is anticipated to be in the range of $940 million to $955 million, a 17% to 19% increase over full year 2024

    "We are very pleased with our strong preliminary revenue performance in the fourth quarter as the team executed exceptionally well and finished the year with significant momentum," said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. "We are also excited to announce the first implants of the new Inspire V neurostimulation system, and a new organizational structure intended to further fuel our continued growth, including the expansion of our leadership team with the hiring of a new Chief Manufacturing and Quality Officer."

    The company announced the appointment of Jason Kelly as its new Chief Manufacturing and Quality Officer effective January 20, 2025. Mr. Kelly comes to Inspire following 10 years at Stryker Corporation most recently in Division Operations Leadership in Kalamazoo, Michigan, and including Advanced Operations in Cork, Ireland. We believe his experience and leadership will provide the skills to lead our Supply Chain, Quality Assurance and Regulatory Operations teams. Mr. Kelly will relocate to Minnesota.

    To fuel our continued growth and advance the adoption of Inspire therapy, the Company implemented the following organizational changes:

    Carlton Weatherby will step into the expanded role of Chief Strategy and Growth Officer and lead the U.S. Sales, Marketing, and Strategy teams. Mr. Weatherby joined Inspire in July 2023 as Chief Strategy Officer and has worked closely with the sales organization to help refine the Company's commercial strategy and identify unexploited opportunities for growth. He has 20 years of experience in MedTech, and previously led a $2B+ business with a 1,000+ person U.S. salesforce within Medtronic before joining Inspire. He quickly established a strong understanding of Inspire's end market, a deep appreciation for the business fundamentals, and trusting relationships with core customers and key opinion leaders.

    Randy Ban will transition from the role of Chief Commercial Officer to a newly created role of EVP, Patient Access and Therapy Development. In this role, Mr. Ban will lead the Patient Access and Therapy Development team, a new team at Inspire tasked with enhancing patient outcomes and patient access to Inspire therapy, increasing focus on research and clinical evidence development, and leading our key opinion leader communications and medical society relationships. Mr. Ban has been with Inspire since 2008 and is ideally suited for this critical new role and its potential to further advance Inspire therapy adoption.

    Ivan Lubogo will transition from the role of SVP U.S. Sales to the newly created role of SVP, Strategic Sales. In this role, Mr. Lubogo will lead a new team focused on Integrated Delivery Networks (IDNs), strategic accounts, and Ambulatory Surgical Centers (ASCs). Mr. Lubogo joined Inspire in 2011 and made immediate contributions to the landmark Inspire STAR clinical trial and helped to build and lead the U.S. field team that generated best in class revenue growth while producing strong patient outcomes.

    Joe Sander will be promoted to the role of SVP U.S. Sales. Mr. Sander currently leads the Inspire field team for the Eastern half of the U.S. He joined Inspire in 2014 just prior to the U.S. FDA commercial approval as Area Vice President, and was instrumental in forming the Inspire U.S. commercial team and establishing a customer-focused sales model. Prior to Inspire, Mr. Sander gained his commercial expertise with over 20 years in sales management at both Boston Scientific Corporation and GlaxoSmithKline.

    Finally, Dr. Charisse Sparks, Chief Medical Officer, left Inspire at the beginning of the year to continue on her intended career journey of mentoring and developing others through Board service. 

    "The addition of our new Chief Manufacturing and Quality Officer along with the focused direction of our senior leadership team places the Company in a strong position to continue the growth in therapy adoption of Inspire therapy and to deliver strong value to all of our stakeholders," concluded Mr. Herbert.

    The preliminary, unaudited revenue results described in this press release are estimates only and are subject to revision until Inspire reports its full financial results for 2024 in its Annual Report on Form 10-K.

    Inspire previously announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis Hotel in San Francisco, CA, including a formal company presentation at 8:15 a.m. P.T. on Monday, January 13, 2025.

    About Inspire Medical Systems

    Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire's proprietary Inspire therapy is the first and only FDA, EU MDR and PDMA-approved neurostimulation technology of its kind that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

    For additional information about Inspire, please visit www.inspiresleep.com.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding our preliminary, unaudited fourth quarter and full year results for fiscal 2024, our expectations regarding full year 2025 financial outlook, and our strategy and investments to grow and scale our business, including our new organizational structure. In some cases, you can identify forward-looking statements by terms such as ‘‘may,'' ‘‘will,'' ‘‘should,'' ‘‘expect,'' ‘‘plan,'' ‘‘anticipate,'' ‘‘could,'' "future," "outlook," "guidance," ‘‘intend,'' ‘‘target,'' ‘‘project,'' ‘‘contemplate,'' ‘‘believe,'' ‘‘estimate,'' ‘‘predict,'' ‘‘potential,'' ‘‘continue,'' or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.

    These forward-looking statements are based on management's current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, estimates regarding the annual total addressable market for our Inspire therapy in the U.S. and our market opportunity outside the U.S.; future results of operations, financial position, research and development costs, capital requirements and our needs for additional financing; commercial success and market acceptance of our Inspire therapy; the impact of macroeconomic trends; general and international economic, political, and other risks, including currency, inflation, stock market fluctuations and the uncertain economic environment; challenges experienced by patients in obtaining prior authorization, our ability to achieve and maintain adequate levels of coverage or reimbursement for our Inspire system or any future products we may seek to commercialize; competitive companies and technologies in our industry; our ability to enhance our Inspire system, expand our indications and develop and commercialize additional products; our business model and strategic plans for our products, technologies and business, including our implementation thereof; our ability to accurately forecast customer demand for our Inspire system and manage our inventory; the impact of glucagon-like peptide 1 class of drugs on demand for our Inspire therapy; our dependence on third-party suppliers, contract manufacturers and shipping carriers; consolidation in the healthcare industry; our ability to expand, manage and maintain our direct sales and marketing organization, and to market and sell our Inspire system in markets outside of the U.S.; risks associated with international operations; our ability to manage our growth; our ability to increase the number of active medical centers implanting Inspire therapy; our ability to hire and retain our senior management and other highly qualified personnel; risk of product liability claims; risks related to information technology and cybersecurity; risk of damage to or interruptions at our facilities; our ability to commercialize or obtain regulatory approvals for our Inspire therapy and system, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the U.S. and international markets; and the timing or likelihood of regulatory filings and approvals. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release can be found under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as updated in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and as such factors may be updated from time to time in our other filings with the SEC, which are accessible on the SEC's website at www.sec.gov and the Investors page of our website at www.inspiresleep.com. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, unless required by applicable law, we disclaim any obligation to do so, even if subsequent events cause our views to change. Thus, one should not assume that our silence over time means that actual events are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date after the date of this press release.

    Investor & Media Contact

    Ezgi Yagci

    Vice President, Investor Relations

    [email protected]

    617-549-2443



    Primary Logo

    Get the next $INSP alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $INSP

    DatePrice TargetRatingAnalyst
    11/20/2024$220.00 → $255.00Neutral → Buy
    BofA Securities
    5/8/2024$265.00 → $225.00Buy → Neutral
    BofA Securities
    4/19/2024$285.00Outperform
    RBC Capital Mkts
    3/19/2024$250.00Overweight
    Morgan Stanley
    2/6/2024$278.00Overweight
    KeyBanc Capital Markets
    1/19/2024$245.00Buy
    Jefferies
    1/2/2024$210.00Buy → Hold
    Stifel
    12/13/2023$245.00 → $187.00Overweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $INSP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Inspire Medical Systems upgraded by BofA Securities with a new price target

      BofA Securities upgraded Inspire Medical Systems from Neutral to Buy and set a new price target of $255.00 from $220.00 previously

      11/20/24 7:43:58 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems downgraded by BofA Securities with a new price target

      BofA Securities downgraded Inspire Medical Systems from Buy to Neutral and set a new price target of $225.00 from $265.00 previously

      5/8/24 7:48:44 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • RBC Capital Mkts initiated coverage on Inspire Medical Systems with a new price target

      RBC Capital Mkts initiated coverage of Inspire Medical Systems with a rating of Outperform and set a new price target of $285.00

      4/19/24 7:26:47 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mccormick Shawn exercised 4,000 shares at a strike of $16.00, increasing direct ownership by 17% to 28,046 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      6/6/25 6:06:02 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Officer Rondoni John sold $259,025 worth of shares (1,734 units at $149.38), decreasing direct ownership by 11% to 13,766 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      5/21/25 4:05:14 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Director Ellis Gary Lee was granted 1,266 shares, increasing direct ownership by 28% to 5,861 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      5/5/25 8:26:47 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inspire Medical Systems, Inc. to Present at the Truist Securities MedTech Conference

      MINNEAPOLIS, June 03, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025. Inspire is scheduled to present at 11:20 a.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at https://investors.inspiresl

      6/3/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems, Inc. to Participate in the Wells Fargo 2025 MedTech Innovation Spotlight

      MINNEAPOLIS, May 30, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, announced today that its management team will participate in the Wells Fargo 2025 MedTech Innovation Spotlight on Friday, June 13, 2025. Inspire is scheduled to present at 12:00 p.m. Eastern Time. The presentation will be accessible via a live webcast here. A webcast replay of the presentation will be available for two weeks following the presentation in the Event Archive section of Inspire's Investor website at https://investor

      5/30/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook

      Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2025. Recent Business Highlights Generated revenue of $201.3 million in the first quarter of 2025, a 23% increase over the same quarter last yearAchieved gross margin of 84.7% in the first quarter of 2025Generated earnings per share of $0.10 in

      5/5/25 4:02:00 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    SEC Filings

    See more
    • Inspire Medical Systems Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Inspire Medical Systems, Inc. (0001609550) (Filer)

      6/13/25 6:19:04 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Inspire Medical Systems Inc.

      SD - Inspire Medical Systems, Inc. (0001609550) (Filer)

      5/30/25 4:12:28 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • SEC Form 144 filed by Inspire Medical Systems Inc.

      144 - Inspire Medical Systems, Inc. (0001609550) (Subject)

      5/19/25 4:01:53 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 21, 2023 - FDA Roundup: March 21, 2023

      For Immediate Release: March 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA completed its second pre-market consultation for a human food made from cultured animal cells. The firm will use animal cell culture technology to take living cells from chickens and grow the cells in a controlled environment to make the cultured

      3/21/23 3:12:46 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Financials

    Live finance-specific insights

    See more
    • Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook

      Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire, or the company), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter ended March 31, 2025. Recent Business Highlights Generated revenue of $201.3 million in the first quarter of 2025, a 23% increase over the same quarter last yearAchieved gross margin of 84.7% in the first quarter of 2025Generated earnings per share of $0.10 in

      5/5/25 4:02:00 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems, Inc. to Report First Quarter 2025 Financial Results on May 5, 2025

      MINNEAPOLIS, April 01, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire) will release financial results for the first quarter 2025 after the close of trading on Monday, May 5. Inspire's management team will host a corresponding conference call beginning at 5:00 p.m. Eastern Time to discuss the financial results and recent business developments. A webcast of the call will be accessible via the Investor Relations page of the Inspire website or through this link: Inspire's Q1 2025 earnings call webcast. For those not planning to ask a question of management, the Company recommends listening via the webcast. If you plan to ask a question, please use the following l

      4/1/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Inspire Medical Systems, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results and Updates 2025 Outlook

      MINNEAPOLIS, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea, today reported financial results for the quarter and year ended December 31, 2024. Recent Business Highlights and Full Year 2025 Guidance Generated revenue of $239.7 million for the fourth quarter of 2024, a 25% increase over the same quarter last year, and revenue of $802.8 million for full year 2024, a 28% increase over full year 2023Achieved gross margin of 85.0% for the fourth quarter of 2024Repo

      2/10/25 4:02:00 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sparks Charisse Y bought $15,350 worth of shares (100 units at $153.50), increasing direct ownership by 11% to 998 units (SEC Form 4)

      4 - Inspire Medical Systems, Inc. (0001609550) (Issuer)

      1/24/24 4:32:03 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

      SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

      11/12/24 10:32:14 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Inspire Medical Systems Inc.

      SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

      10/4/24 2:09:06 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Inspire Medical Systems Inc. (Amendment)

      SC 13G/A - Inspire Medical Systems, Inc. (0001609550) (Subject)

      2/13/24 5:06:20 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care

    $INSP
    Leadership Updates

    Live Leadership Updates

    See more
    • Inspire Medical Systems, Inc. Announces the Addition of Paul T. Hoff, M.D., M.S. and Ruchir P. Patel, M.D., F.A.C.P. as Vice President, Senior Medical Directors

      MINNEAPOLIS, April 21, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE:INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced that two leading physicians in the field of sleep medicine and sleep surgery, Paul T. Hoff, M.D., M.S., an otolaryngologist, and Ruchir P. Patel, M.D., F.A.C.P., a sleep medicine specialist, will join Inspire in Vice President, Senior Medical Director roles, effective April 21 and June 2 respectively.   "Dr. Hoff and Dr. Patel are widely regarded as experts and thought leaders in their respective fields, a

      4/21/25 8:00:00 AM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Presidio Medical™ Announces Appointment of Richard J. Buchholz to Join its Board of Directors

      Presidio Medical, Inc., a clinical stage company developing a transformational neuromodulation platform, is pleased to announce Richard J. Buchholz will join its Board of Directors. Rick is the Chief Financial Officer of Inspire Medical Systems, Inc. (NYSE:INSP), where he has played a pivotal role in driving strategic financial and operational growth for the global leader in the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. "We are excited that Rick is joining the Board of Directors of Presidio Medical at this critical time in our company's journey. His leadership and financial acumen will be instrumental in advanc

      12/5/24 12:12:00 PM ET
      $INSP
      Medical/Dental Instruments
      Health Care
    • Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

      NEW YORK, Sept. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from

      9/6/24 6:43:00 PM ET
      $AAL
      $ADMA
      $ADNT
      $AMCX
      Air Freight/Delivery Services
      Consumer Discretionary
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care